Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin + Pomalidomide + Dexamethasone vs Bortezomib + Pomalidomide + Dexamethasone in RRMM
NCT06956170Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Started Feb 2022; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06956170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956170.